1.Kuroda K, Okumura K, Isogai H and Isogai E (2015) The human cathelicidin antimicrobial peptide LL-37 and mimics are potential anticancer drugs. Front. Oncol. 5:144. doi: 10.3389/fonc.2015.00144
2.Parvy , J.P., Yu, Y., Dostalova, A., Kondo, S., Kurjan, A., Bulet, P., Lemaître, B., Vidal, M., Cordero, J. M. The antimicrobial peptide defensin cooperates with tumour necrosis factor to drive tumour cell death in Drosophila. eLife 2019;8:e45061
3.Wu WK, Sung JJ, To KF, Yu L, Li HT, Li ZJ, et al. The host defense peptide LL-37 activates the tumor-suppressing bone morphogenetic protein signaling via inhibition of proteasome in gastric cancer cells. J Cell Physiol (2010) 223(1):178–86. doi:10.1002/jcp.22026
4.Wang G, Mishra B, Epand RF, Epand RM. High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments. Biochim Biophys Acta (2014) 1838(9):2160–72. doi:10.1016/j. bbamem.2014.01.016
5.Goitsuka, R.; Chen, C.L.; Benyon, L.; Asano, Y.; Kitamura, D.; Cooper, M.D. Chicken cathelicidin-B1, an antimicrobial guardian at the mucosal M cell gateway. Proc. Natl. Acad. Sci. USA 2007, 104, 15063–15068.
6.Xiao, Y; Cai, Y.; Bommineni, Y.R.; Fernando, S.C.; Prakash, O.; Gilliland, S.E.; Zhang, G. Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity. J. Biol. Chem. 2006, 281, 2858–2867
7.Achanta, M.; Sunkara, L.T.; Dai, G.; Bommineni, Y.R.; Jiang, W.; Zhang, G. Tissue expression and developmental regulation of chicken cathelicidin antimicrobial peptides. J. Anim. Sci. Biotechnol. 2012, 3, 15
8.Cuperus T, van Dijk A, Matthijs MG, Veldhuizen EJ, Haagsman HP (2016) Protective effect of in ovo treatment with the chicken cathelicidin analog D-CATH-2 against avian pathogenic E. coli. Sci Rep 6:26622
9.Cuperus, T.; Coorens, M.; van Dijk, A.; Haagsman, H.P. Avian host defense peptides. Dev. Comp. Immunol. 2013, 41, 352–369
10.Lee, M.O.; Jang, H.J.; Rengaraj, D.; Yang, S.Y.; Han, J.Y.; Lamont, S.J.; Womack, J.E. Tissue expression and antibacterial activity of host defense peptides in chicken. BMC Vet. Res. 2016, 12, 231
11.Lee, M.O.; Kim, E.H.; Jang, H.J.; Park, M.N.; Woo, H.J.; Han, J.Y.; Womack, J.E. Effects of a single nucleotide polymorphism in the chicken NK-lysin gene on antimicrobial activity and cytotoxicity of cancer cells. Proc. Natl. Acad. Sci. USA 2012, 109, 12087–12092.
12.Zasloff, M. Antimicrobial Peptides of Multicellular Organisms: My Perspective. Adv. Exp. Med. Biol. 2019, 1117, 3–6.
13.Van Dijk A, Tersteeg-Zijderveld MH, Tjeerdsma-van Bokhoven JL, Jansman AJ, Veldhuizen EJ, Haagsman HP (2009) Chicken heterophils are recruited to the site of Salmonella infection and release antibacterial mature Cathelicidin-2 upon stimulation with LPS. Mol Immunol 46(7):1517–1526
14.Van Dijk A, van Eldik M, Veldhuizen EJ, Tjeerdsma-van Bokhoven HL, de Zoete MR, Bikker FJ, Haagsman HP (2016) Immunomodulatory and anti-inflammatory activities of chicken cathelicidin-2 derived peptides. PLos One 11(2):e0147919
15.Coorens M, Schneider VA, de Groot AM, van Dijk A, Meijerink M, Wells JM, Scheenstra MR, Veldhuizen EJ, Haagsman HP (2017) Cathelicidins inhibit escherichia coli–induced tlr2 and tlr4 activation in a viability-dependent manner. J Immunol 199(4):1418–1428
16.Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control (2003) 10(2):159–65.
17.Peng L, Du W, Balhuizen MD, Haagsman HP, de Haan CAM, Veldhuizen EJA (2020a) Antiviral activity of chicken cathelicidin B1 against influenza A virus. Front Microbiol 11:426
18.Peng L, Du W, Balhuizen MD, Haagsman HP, de Haan CAM, Veldhuizen EJA (2020b) The immunomodulatory effect of cathelicidin-B1 on chicken macrophages. Veterinary Research volume 51, 122
19.Chen, X., Zoua, X., Qi,G., Tanga, Y., Guo, Y., Si, J., Liang, L. Roles and Mechanisms of Human Cathelicidin LL-37 in Cancer. Cell Physiol Biochem 2018;47:1060-1073
20.Blagoskonny MV, Pardee AB: Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res, 2001, 61, 4301–4305
21.Nurse P: Cyclin dependent kinases and cell cycle control (Nobel lecture). Chembiochem, 2002, 3, 596–603.
22.Ghosh, R., A.M. Ott, D. Seetharam, T.J. Slaga, A.P. Kumar, Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: therapeutic implications? Melanoma Res. 13 (2003) 119–127.
23.Johansson, Jan, Gudmundur H Gudmundsson, Martı́n E Rottenberg, Kurt D Berndt, and Birgitta Agerberth. 1998. "Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37." Journal of Biological Chemistry 273 (6):3718-3724.
24.Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J (1999) 341(Pt 3):501–13. doi:10.1042/0264-6021:3410501
25.Dennison SR, Whittaker M, Harris F, Phoenix DA. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci (2006) 7(6):487–99. doi:10.2174/138920306779025611
26.Yacoub HA, Ahmed M. Elazzazy, Maged M.Mahmoud,Mohamed Nabih Baeshen, Omar A. Al-Maghrabi, Saleh Alkarim, Ekram S. Ahmed, Hussein A. Almehdar, Vladimir N. Uversky (2016) Chicken cathelicidins as potent intrinsically disordered biocides with antimicrobial activity against infectious pathogens. Developmental and Comparative Immunology (65). 8-24.
27.Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem (2005) 280(13):12316–29. doi:10.1074/ jbc.M413406200
28.Huang YB, Wang XF, Wang HY, Liu Y, Chen Y. Studies on mechanism of action of anticancer peptides by modulation of hydrophobicity within a defined structural framework. Mol Cancer Ther (2011) 10(3):416–26. doi:10.1158/1535-7163. MCT-10-0811
29.Huang, Hsuan‐Jen, Christopher R Ross, and Frank Blecha. 1997. "Chemoattractant properties of PR‐39, a neutrophil antibacterial peptide." Journal of leukocyte biology 61 (5):624-629.
30.Riedl S, Zweytick D, Lohner K. Membrane-active host defense peptides – challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 164(8):766–81. doi:10.1016/j.chemphyslip.2011.09.004
31.Harris F, Dennison SR, Singh J, Phoenix DA. On the selectivity and efficacy of defense peptides with respect to cancer cells. Med Res Rev (2013) 33(1):190–234. doi:10.1002/med.20252
32.Simons K, Ikonen E. How cells handle cholesterol. Science (2000) 290(5497):1721–6. doi:10.1126/science.290.5497.1721
33.Matsuzaki K, Sugishita K, Fujii N, Miyajima K. Molecular basis for membrane selectivity of an antimicrobial peptide, magainin 2. Biochemistry (1995) 34(10):3423–9. doi:10.1021/bi00010a034
34.Wojcik C, Sawicki W, Marianowski P, Benchaib M, Czyba JC, Guerin JF. Cyclodextrin enhances spermicidal effects of magainin-2-amide. Contraception (2000) 62(2):99–103. doi:10.1016/S0010-7824(00)00143-8
35.Tokumaru, Sho, Koji Sayama, Yuji Shirakata, Hitoshi Komatsuzawa, Kazuhisa Ouhara, Yasushi Hanakawa, Yoko Yahata, Xiuju Dai, Mikiko Tohyama, and Hiroshi Nagai. 2005. "Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37." The journal of immunology 175 (7):4662-4668.
36.Steiner H, Andreu D, Merrifield RB. Binding and action of cecropin and cecropin analogues: antibacterial peptides from insects. Biochim Biophys Acta (1988) 939(2):260–6. doi:10.1016/0005-2736(88)90069-7
37.Higgins GS, O’Cathail SM, Muschel RJ, McKenna WG. Drug radiotherapy combinations: review of previous failures and reasons for future optimism. Cancer Treat Rev (2015) 41(2):105–13. doi:10.1016/j.ctrv.2014.12.012
38.Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des (2010) 16(1):3–10. doi:10.2174/138161210789941847
39.Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev (2014) 40(7):862–71. doi:10.1016/j. ctrv.2014.03.004
40.Vincenzi B, Imperatori M, Silletta M, Marrucci E, Santini D, Tonini G. Emerging kinase inhibitors of the treatment of gastric cancer. Expert Opin Emerg Drugs (2015):1–15. doi:10.1517/14728214.2015.1051467
41.Karczmarek-Borowska B, Salek-Zan A. Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn) (2015) 19(2):87–92. doi:10.5114/wo.2014.43495 44. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem (2009) 107(6):1053–62. doi:10.1002/jcb.22214
42.Reddy, KVR, RD Yedery, and C Aranha. 2004. "Antimicrobial peptides: premises and promises." International journal of antimicrobial agents 24 (6):536-547.
43.Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev (2009) 61(14):1250–75. doi:10.1016/j.addr.2009.05.0105
44.Li Y, Cozzi PJ. Angiogenesis as a strategic target for prostate cancer therapy. Med Res Rev (2010) 30(1):23–66. doi:10.1002/med.20161
45.Breen EC, Walsh JJ. Tubulin-targeting agents in hybrid drugs. Curr Med Chem (2010) 17(7):609–39. doi:10.2174/092986710790416254
46.Rosales, Carlos. 2018. "Neutrophil: a cell with many roles in inflammation or several cell types?" Frontiers in Physiology 9:113.
47.Zhang, Jun-Ming, and Jianxiong An. 2007. "Cytokines, inflammation and pain." International anesthesiology clinics 45 (2):27.
- Warrington, Richard, Wade Watson, Harold L Kim, and Francesca Romana Antonetti. 2011. "An introduction to immunology and immunopathology." Allergy, Asthma & Clinical Immunology 7 (1):S1.
- Yang ST, Shin SY, Lee CW, Kim YC, Hahm KS, Kim JI. Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure. FEBS Lett (2003) 540(1–3):229–33. doi:10.1016/ S0014-5793(03)00266-7
50.Mader JS, Mookherjee N, Hancock RE, Bleackley RC. The human host defense peptide LL-37 induces apoptosis in a calpain- and apoptosis-inducing factordependent manner involving Bax activity. Mol Cancer Res (2009) 7(5):689–702. doi:10.1158/1541-7786.MCR-08-0274
51.Chuang CM, Monie A, Wu A, Mao CP, Hung CF. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer. Hum Gene Ther (2009) 20(4):303–13. doi:10.1089/ hum.2008.124
52.Shojaei, Farbod. 2012. "Anti-angiogenesis therapy in cancer: current challenges and future perspectives." Cancer letters 320 (2):130-137.
53.Savarese, Diane MF, Gayle Savy, Linda Vahdat, Paul E Wischmeyer, and Barbara Corey. 2003. "Prevention of chemotherapy and radiation toxicity with glutamine." Cancer treatment reviews 29 (6):501-513.
54.Sato, Emi, Shinichi Imafuku, Kazunari Ishii, Ryota Itoh, Bin Chou, Toshinori Soejima, Juichiro Nakayama, and Kenji Hiromatsu. 2013. "Vitamin D-dependent cathelicidin inhibits Mycobacterium marinum infection in human monocytic cells." Journal of dermatological science 70 (3):166-172.
55.Iwasaki T, Ishibashi J, Tanaka H, Sato M, Asaoka A, Taylor D, Yamakawa M. 2009. Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30:660–668. DOI: https://doi.org/10.1016/j.peptides
56.Lin, H.L., T.Y. Liu, G.Y. Chau, W.Y. Lui, C.W. Chi, Comparison of 2-methoxyestradiolinduced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species, Cancer 89 (2000) 983–994.
57.Qadan, L.R., C.M. Perez-Stable, C. Anderson, G. D'Ippolito, A. Herron, G.A. Howard, B.A. Roos, BA, 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer, Biochem. Biophys. Res. Commun. 285 (2001) 1259–1266.
58.Kumar, A.P., G.E. Garcia, T.J. Slaga, 2-methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells, Mol. Carcinog. 31 (2001) 111–124.
59.Ray, G. G. Dhar, P.J. Van Veldhuizen, S. Banerjee, N.K. Saxena, K. Sengupta, S.K. Banerjee, Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways, Biochemistry 45 (2006) 3703–3713.
60.Fukui, M., B.T. Zhu, Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells, Mol. Carcinog. 48 (2009) 66–78.
61.Stander, B.A., S. Marais, C.J. Vorster, A.M. Joubert, In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line, J. Steroid Biochem. Mol. Biol. 119 (2010) 149–160.
62.Coico, Richard, and Geoffrey Sunshine. 2015. Immunology: a short course: John Wiley & Sons.
63.Wendell, K.L., L. Wilson, M.A. Jordan, Mitotic block in HeLa cells by vinblastine: ultrastructural changes in kinetochore-microtubule attachment and in centrosomes, J. Cell Sci. 104 (Pt 2) (1993) 261–274.
64.Vasquez, R.J., B. Howell, A.M. Yvon, P. Wadsworth, L. Cassimeris, Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro, Mol. Biol. Cell 8 (1997) 973–985.
65.Jordan, M.A., L. Wilson, Microtubules and actin filaments: dynamic targets for cancer chemotherapy, Curr. Opin. Cell Biol. 10 (1998) 123–130.
66.Wang, T.H., D.M. Popp, H.S. Wang, M. Saitoh, J.G. Mural, D.C. Henley, H. Ichijo, J. Wimalasena, Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and -independent pathways in ovarian cancer cells, J. Biol. Chem. 274 (1999) 8208–8216.
67.Mollinedo, F., C. Gajate, Microtubules, microtubule-interfering agents and apoptosis, Apoptosis 8 (2003) 413–450.
- Kościuczuk, Ewa M, Paweł Lisowski, Justyna Jarczak, Nina Strzałkowska, Artur Jóźwik, Jarosław Horbańczuk, Józef Krzyżewski, Lech Zwierzchowski, and Emilia Bagnicka. 2012. "Cathelicidins: family of antimicrobial peptides. A review." Molecular biology reports 39 (12):10957-10970.
69.Yang YH, Zheng GG, Li G, Zhang B, Song YH, Wu KF. Expression of LL-37/ hCAP-18 gene in human leukemia cells. Leuk Res (2003) 27(10):947–50. doi:10.1016/S0145-2126(03)00020-1 89. Ren SX, Cheng AS, To KF, Tong JH, Li MS, Shen J, et al. Host immune defense peptide LL-37 activates caspase-independent apoptosis and suppresses colon cancer. Cancer Res (2012) 72(24):6512–23. doi:10.1158/0008-5472. CAN-12-2359
70.Ren SX, Shen J, Cheng AS, Lu L, Chan RL, Li ZJ, et al. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One (2013) 8(5):e63641. doi:10.1371/ journal.pone.0063641
- Howell, Michael D, James F Jones, Kevin O Kisich, Joanne E Streib, Richard L Gallo, and Donald YM Leung. 2004. "Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum." The Journal of Immunology 172 (3):1763-1767.
- Guaní-Guerra, Eduardo, Teresa Santos-Mendoza, Saúl O Lugo-Reyes, and Luis M Terán. 2010. "Antimicrobial peptides: general overview and clinical implications in human health and disease." Clinical immunology 135 (1):1-11.
- Bandurska, Katarzyna, Agnieszka Berdowska, Renata Barczyńska‐Felusiak, and Piotr Krupa. 2015. "Unique features of human cathelicidin LL‐37." Biofactors 41 (5):289-300.
74.Yang, De, Qian Chen, Albert P Schmidt, G Mark Anderson, Ji Ming Wang, Joseph Wooters, Joost J Oppenheim, and Oleg Chertov. 2000. "LL-37, the neutrophil granule–and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor–like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells." The Journal of experimental medicine 192 (7):1069-1074.
- Baskar, Rajamanickam, Kuo Ann Lee, Richard Yeo, and Kheng-Wei Yeoh. 2012. "Cancer and radiation therapy: current advances and future directions." International journal of medical sciences 9 (3):193.
76.Crack, LR, L Jones, GN Malavige, V Patel, and GS Ogg. 2012. "Human antimicrobial peptides LL‐37 and human β‐defensin‐2 reduce viral replication in keratinocytes infected with varicella zoster virus." Clinical and Experimental Dermatology: Experimental dermatology 37 (5):534-543.
77.Lai, Yuping, and Richard L Gallo. 2009. "AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense." Trends in immunology 30 (3):131-141.
78.Arruebo, Manuel, Nuria Vilaboa, Berta Sáez-Gutierrez, Julio Lambea, Alejandro Tres, Mónica Valladares, and África González-Fernández. 2011. "Assessment of the evolution of cancer treatment therapies." Cancers 3 (3):3279-3330.
79.Ventola, C Lee. 2017. "Cancer immunotherapy, part 1: current strategies and agents." Pharmacy and Therapeutics 42 (6):375.
80.Li, Yifeng, Xia Li, and Guangshun Wang. 2006. "Cloning, expression, isotope labeling, and purification of human antimicrobial peptide LL-37 in Escherichia coli for NMR studies." Protein expression and purification 47 (2):498-505.
81.Den HERTOG, Alice L, Jan van MARLE, Henk A van VEEN, Wim van't HOF, Jan GM Bolscher, Enno CI Veerman, and Arie V NIEUW AMERONGEN. 2005. "Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane." Biochemical Journal 388 (2):689-695.
82.Barlow, Peter G, Emily Gwyer Findlay, Silke M Currie, and Donald J Davidson. 2014. "Antiviral potential of cathelicidins." Future microbiology 9 (1):55-73.
83.Ni, L., and Lu, J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018,7(9):4509-4516.doi: 10.1002/cam4.1700.
84.Idriss, Haitham T, and James H Naismith. 2000. "TNFα and the TNF receptor superfamily: Structure‐function relationship (s)." Microscopy research and technique 50 (3):184-195.
85.Bucki, Robert, Katarzyna Leszczyńska, Andrzej Namiot, and Wojciech Sokołowski. 2010. "Cathelicidin LL-37: a multitask antimicrobial peptide." Archivum immunologiae et therapiae experimentalis 58 (1):15-25.
86.Bots, Michael, and Jan Paul Medema. 2006. "Granzymes at a glance." Journal of cell science 119 (24):5011-5014.
87.Mader, Jamie S, Catherine Ewen, Robert EW Hancock, and Robert C Bleackley. 2011. "The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells." Journal of Immunotherapy 34 (3):229-235.
88.Carretero, Marta, Maria J Escamez, Marta Garcia, Blanca Duarte, Almudena Holguín, Luisa Retamosa, Jose L Jorcano, Marcela Del Río, and Fernando Larcher. 2008. "In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37." Journal of Investigative Dermatology 128 (1):223-236.
89.Chaplin, David D. 2010. "Overview of the immune response." Journal of Allergy and Clinical Immunology 125 (2):S3-S23.
90.Reinholz, Markus, Thomas Ruzicka, and Jürgen Schauber. 2012. "Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease." Annals of dermatology 24 (2):126-135.
91.Piktel, Ewelina, Katarzyna Niemirowicz, Urszula Wnorowska, Marzena Wątek, Tomasz Wollny, Katarzyna Głuszek, Stanisław Góźdź, Ilya Levental, and Robert Bucki. 2016. "The role of cathelicidin LL-37 in cancer development." Archivum immunologiae et therapiae experimentalis 64 (1):33-46.
92.Wu WK, Wang G, Coffelt SB, Betancourt AM, Lee CW, Fan D, et al. Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications. Int J Cancer (2010) 127(8):1741–7. doi:10.1002/ijc.25489
93.Wu, William Ka Kei, Clover Ching Man Wong, Zhi Jie Li, Lin Zhang, Shun Xiang Ren, and Chi Hin Cho. 2010. "Cathelicidins in inflammation and tissue repair: potential therapeutic applications for gastrointestinal disorders." Acta Pharmacologica Sinica 31 (9):1118-1122.
94.An, Li-Li, Xiao-Tong Ma, Ying-Hua Yang, Yong-Min Lin, Yu-Hua Song, and Ke-Fu Wu. 2005. "Marked reduction of LL-37/hCAP-18, an antimicrobial peptide, in patients with acute myeloid leukemia." International journal of hematology 81 (1):45-47.
95.Liu, W., Hu, M., Wang, Y., Sun, B., Guo, Y., Xu, Z., Li, J., and Han, B. Overexpression of interleukin-18 protein reduces viability and induces apoptosis of tongue squamous cell carcinoma cells by activation of glycogen synthase kinase-3β signaling. ONCOLOGY REPORTS 33: 1049-1056, 2015
96.Livak, K.J and Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.:732-741.
97.Frajacomo, Fernando Tadeu Trevisan, Camila de Souza Padilha, Poliana Camila Marinello, Flávia Alessandra Guarnier, Rubens Cecchini, José Alberto R Duarte, and Rafael Deminice. 2016. "Solid Ehrlich carcinoma reproduces functional and biological characteristics of cancer cachexia." Life sciences 162:47-53.
98.Hiebert, Paul R, and David J Granville. 2012. "Granzyme B in injury, inflammation, and repair." Trends in molecular medicine 18 (12)